Abbott Laboratories (ABT)
$
128.9
+0.36 (0.28%)
Key metrics
Financial statements
Free cash flow per share
3.9548
Market cap
224.4 Billion
Price to sales ratio
5.1173
Debt to equity
0.2540
Current ratio
1.7034
Income quality
0.6524
Average inventory
6.8 Billion
ROE
0.2824
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abbott Laboratories, along with its subsidiaries, is engaged in the discovery, development, manufacturing, and global sale of health care products, operating across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The EBITDA is $10,834,000,000.00 a key indicator of the company's operational profitability. Within the Established Pharmaceutical Products segment, the company markets generic pharmaceuticals to address conditions such as pancreatic exocrine insufficiency and dyslipidemia, as well as providing critical anti-infectives like clarithromycin and an influenza vaccine. The operating expenses amount to $14,474,000,000.00 encompassing various operational costs incurred, while the company reported selling, general, and administrative expenses of $11,651,000,000.00 indicating its operational overhead costs. Furthermore, the diluted EPS is $7.64 accounting for potential share dilution. The Diagnostic Products segment enhances health care with laboratory systems focused on immunoassay and clinical chemistry, alongside molecular diagnostics for infectious agents. The Nutritional Products segment delivers essential nutritional solutions for both pediatric and adult populations, while the Medical Devices segment offers innovative treatments for cardiovascular diseases and diabetes management. Abbott Laboratories, founded in 1888 and based in North Chicago, Illinois, has established itself as a leader in the health care sector. The stock is reasonably priced at $136.04 appealing to a broad range of investors. With a large market capitalization of $224,358,349,894.00 the company is a dominant player in the health care industry, contributing significantly to the overall market landscape. The stock has a high average trading volume of 6,260,662.00 indicating strong liquidity. It is a key player in the Medical - Devices industry, driving innovation and growth, and belongs to the Healthcare sector, further affirming its stature within the competitive health care market. Abbott Laboratories’ commitment to advancement and quality in health care solutions continues to position it for sustained success and relevance.
Is Abbott Laboratories (ABT) a good investment?
Investing in Abbott Laboratories (ABT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is Abbott Laboratories (ABT)'s stock forecast?
Analysts predict Abbott Laboratories stock to fluctuate between $110.86 (low) and $141.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abbott Laboratories's market capitalization?
As of 2025-11-28, Abbott Laboratories's market cap is $224,358,349,894, based on 1,740,561,287 outstanding shares.
How does Abbott Laboratories compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Abbott Laboratories has a Lower Market-Cap, indicating a difference in performance.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays dividends. The current dividend yield is 1.82%, with a payout of $0.59 per share.
How can I buy Abbott Laboratories (ABT) stock?
To buy Abbott Laboratories (ABT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABT. Place an order (Market, Limit, etc.).
What is the best time to invest in Abbott Laboratories?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Abbott Laboratories stock ever split?
Abbott Laboratories's last stock split was 5000:2399 on 2013-01-02.
How did Abbott Laboratories perform in the last earnings report?
Revenue: $41,950,000,000 | EPS: $7.67 | Growth: 132.42%.
Where can I find Abbott Laboratories's investor relations reports?
Visit https://www.abbott.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abbott Laboratories?
You can explore historical data from here
What is the all-time high and low for Abbott Laboratories stock?
All-time high: $142.60 (2021-12-27) | All-time low: $89.67 (2023-10-12).
What are the key trends affecting Abbott Laboratories stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
reuters.com
Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some units may report falsely low glucose readings.
defenseworld.net
Boston Research and Management Inc. lowered its position in Abbott Laboratories (NYSE: ABT) by 1.6% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 58,395 shares of the healthcare product maker's stock after selling 921 shares during the quarter. Abbott Laboratories comprises 1.9%
fool.com
These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding.
fool.com
Abbott and Medtronic are innovative healthcare leaders that generate consistent revenue and profits. They also have attractive long-term prospects and have consistently raised their dividend payouts.
marketwatch.com
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
barrons.com
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
reuters.com
Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business.
prnewswire.com
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments Acquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier lives Exact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testing Acquisition will be immediately accretive to Abbott's revenue growth and gross margin Abbott to host investor call today at 8 a.m. Central Time/9 a.m.
barrons.com
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
reuters.com
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.
See all news
